Novilora has launched in the US, bringing a science-based approach to supporting nerve health for people living through and beyond cancer treatment.  

Formulated by Italian internist and oncologist Dr Raffaele Migliaccio and sold in Europe as OnLife, Novilora combines palmitoylethanolamide (PEA) with a defined profile of fatty acids built around biologic pathways relevant to peripheral nerve structure, signalling and cellular function. 

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effects of cancer treatment. It often causes motor and sensory impairment, including reduced or lost peripheral sensation, as well as affecting the autonomic nervous system, leading to changes in heart rate, gastric, intestinal, and sexual function, and sleep-wake cycles. 

Research has found that approximately 68% of patients experience CIPN within the first month after chemotherapy, with symptoms persisting in approximately 30% six months or more after treatment. 

Novilora has been evaluated in the peer-reviewed STEFANO study, a multicentre observational study involving 146 breast and colon cancer patients experiencing established CIPN following paclitaxel or oxaliplatin-based chemotherapy.  

After three months of use, researchers observed improvements and stabilisation across measures of sensory and motor neuropathy, with patient-reported outcomes also showing improvements in symptoms and everyday function.  

Among patients with paclitaxel-induced neuropathy, 46% reported reductions in sensory symptoms and functional limitations and 38% reported reductions in motor symptoms and functional limitations. The study also reported improvements in quality-of-life measures. 

“Chemotherapy can save and extend lives, but for many patients, its effects do not simply disappear when treatment ends,” said Dr Migliaccio. “Peripheral neuropathy can affect something as basic as walking comfortably, maintaining balance, buttoning a shirt or sleeping through the night. I developed this formulation with a broader goal in mind: to support nerve health and help make life during and after cancer treatment more manageable.”